Multifunctional Effect of Human Serum Albumin Reduces Alzheimer's Disease Related Pathologies in the 3xTg Mouse Model

Journal of Alzheimer's Disease

Volumn 50, Issue 1, 2016, Pages 175-188

  Ezra, Assaf ^a   Rabinovich Nikitin, Inna ^a   Rabinovich Toidman, Polina ^a   Solomon, Beka ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Albumin; Alzheimer's disease; blood brain barrier; cognitive impairment; inflammation; myelin; therapy

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; HUMAN SERUM ALBUMIN; MYELIN; TAU PROTEIN; TUBULIN; ALBUMINOID; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); AMYLOID PRECURSOR PROTEIN; CALCIUM; PEPTIDE FRAGMENT; PRESENILIN 1;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; ENCEPHALITIS; HUMAN; HUMAN CELL; MALE; MICROTUBULE; MOUSE; NEUROBLASTOMA CELL LINE; NONHUMAN; PRIORITY JOURNAL; THERAPY EFFECT; ANIMAL; BRAIN; C57BL MOUSE; COGNITION DISORDERS; COMPLICATION; DISEASE MODEL; DRUG DELIVERY SYSTEM; DRUG EFFECTS; GENETICS; METABOLISM; MUTATION; NEUROBLASTOMA; NEUROPSYCHOLOGICAL TEST; PATHOLOGY; TRANSGENIC MOUSE; TUMOR CELL LINE;

ALBUMINS; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; CALCIUM; CELL LINE, TUMOR; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; ENCEPHALITIS; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUTATION; NEUROBLASTOMA; NEUROPSYCHOLOGICAL TESTS; PEPTIDE FRAGMENTS; PRESENILIN-1; TAU PROTEINS;

EID: 84954160267     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-150694     Document Type: Article

References (71)

1. Paradise M,Walker Z, Cooper C, Blizard R, Regan C, Katona C, Livingston G (2009) Prediction of survival in Alzheimer's disease-The LASER-AD longitudinal study. Int J Geriatr Psychiatry 24, 739-747.
2. Cvetkovic-Dozic D, Skender-Gazibara M, Dozic S (2001) Neuropathological hallmarks of Alzheimer's disease. Arch Oncol 9, 5-7.
3. Akiyama H, Barger S, Barnum S, Bradt B (2000) Inflammation and Alzheimer's disease. Neurobiol Aging 21, 383-421.
4. Perry G, Cash AD, Smith MA (2002) Alzheimer disease and oxidative stress. J Biomed Biotechnol 2, 120-123.
5. White AR, Multhaup G, Maher F, Bellingham S, Camakaris J, Zheng H, Bush AI, Beyreuther K, Masters CL, Cappai R (1999) The Alzheimer's disease amyloid precursor protein modulates copper-induced toxicity and oxidative stress in primary neuronal cultures. J Neurosci 19, 9170-9179.
6. Multhaup G, Schlicksupp A, Hesse L, Beher D, Ruppert T, Masters CL, BeyreutherK(1996) The amyloid precursor protein of Alzheimer's disease in the reduction of copper(II) to copper(I) . Science 271, 1406-1409.
7. Bowman GL, Kaye JA, Quinn JF (2012) Dyslipidemia and blood-brain barrier integrity in Alzheimer's disease. Curr Gerontol Geriatr Res 2012, 184042.
8. Quinlan GJ, Martin GS, Evans TW (2005) Albumin: Biochemical properties and therapeutic potential. Hepatology 41, 1211-1219.
9. Zunszain PA, Ghuman J, McDonagh AF, Curry S (2008) Crystallographic analysis of human serum albumin complexed with 4Z,15E-bilirubin-IXalpha. J Mol Biol 381, 394-406.
10. Zoellner H, Hou JY, Lovery M, Kingham J, Srivastava M, Bielek E, Vanyek E, Binder BR (1999) Inhibition of microvascular endothelial apoptosis in tissue explants by serum albumin. Microvasc Res 57, 162-173.
11. Galeazzi L, Galeazzi R, Valli MB, Corder EH, Giunta S (2002) Albumin protects human red blood cells against Abeta25-35-induced lysis more effectively than ApoE. Neuroreport 13, 2149-2154.
12. Onal C, Unal F, Turantan MI, Uzüm G, Hasanoʇlu A, Kaynar MY (1997) The effect of intraventricular albumin in experimental brain oedema. Acta Neurochir (Wien) 139, 661-668; discussion 668-669.
13. Belayev L, Liu Y, Zhao W, Busto R, Ginsberg MD (2001) Human albumin therapy of acute ischemic stroke: Marked neuroprotective efficacy at moderate doses and with a broad therapeutic window. Stroke 32, 553-560.
14. Tabernero A, Granda B, Medina A, Sánchez-Abarca LI, Lavado E, Medina JM (2002) Albumin promotes neuronal survival by increasing the synthesis and release of glutamate. J Neurochem 81, 881-891.
15. GumET, Swanson RA, Alano C, Liu J, Hong S,Weinstein PR, Panter SS (2004) Human serum albumin and its N-terminal tetrapeptide (DAHK) block oxidant-induced neuronal death. Stroke 35, 590-595.
16. Veering BT, Burm AG, Souverijn JH, Serree JM, Spierdijk J (1990) The effect of age on serum concentrations of albumin and alpha 1-acid glycoprotein. Br J Clin Pharmacol 29, 201-206.
17. Llewellyn DJ, Langa KM, Friedland RP, Lang IA (2010) Serum albumin concentration and cognitive impairment. Curr Alzheimer Res 7, 91-96.
18. Wisniewski HM, Kozlowski PB (1982) Evidence for bloodbrain barrier changes in senile dementia of the Alzheimer type (SDAT) . Ann N Y Acad Sci 396, 119-129.
19. Kuo YM, Kokjohn TA, Kalback W, Luehrs D, Galasko DR, Chevallier N, Koo EH, Emmerling MR, Roher AE (2000) Amyloid-beta peptides interact with plasma proteins and erythrocytes: Implications for their quantitation in plasma. Biochem Biophys Res Commun 268, 750-756.
20. Milojevic J, Melacini G (2011) Stoichiometry and affinity of the human serum albumin-Alzheimer's A peptide interactions. Biophys J 100, 183-192.
21. Biere AL, Ostaszewski B, Stimson ER, Hyman BT, Maggio JE, Selkoe DJ (1996) Amyloid beta-peptide is transported on lipoproteins and albumin in human plasma. J Biol Chem 271, 32916-32922.
22. Yamamoto K, Shimada H, Koh H, Ataka S, Miki T (2014) Serum levels of albumin-amyloid beta complexes are decreased in Alzheimer's disease. Geriatr Gerontol Int 14, 716-723.
23. Milojevic J, Raditsis A, Melacini G (2009) Human serum albumin inhibits Abeta fibrillization through a "monomercompetitor" mechanism. Biophys J 97, 2585-2594.
24. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, Laferla FM (2003) Triple-transgenic model of Alzheimer's disease with plaques and tangles: Intracellular A( and synaptic dysfunction. Neuron 39, 409-421.
25. Belinson H, Lev D, Masliah E, Michaelson DM (2008) Activation of the amyloid cascade in apolipoprotein E4 transgenic mice induces lysosomal activation and neurodegeneration resulting in marked cognitive deficits. J Neurosci 28, 4690-4701.
26. Avrahami L, Farfara D, Shaham-Kol M, Vassar R, Frenkel D, Eldar-Finkelman H (2013) Inhibition of glycogen synthase kinase-3 ameliorates-amyloid pathology and restores lysosomal acidification and mammalian target of rapamycin activity in the Alzheimer disease mouse model: In vivo and in vitro studies. J Biol Chem 288, 1295-1306.
27. Saura CA, Chen G, Malkani S, Choi S-Y, Takahashi RH, Zhang D, Gouras GK, Kirkwood A, Morris RGM, Shen J (2005) Conditional inactivation of presenilin 1 prevents amyloid accumulation and temporarily rescues contextual and spatial working memory impairments in amyloid precursor protein transgenic mice. J Neurosci 25, 6755-6764.
28. LarsonME,Lesné SE(2012) Soluble Aoligomer production and toxicity. J Neurochem 120 Suppl, 125-139.
29. Walsh DM, Selkoe DJ (2007) A beta oligomers-A decade of discovery. J Neurochem 101, 1172-1184.
30. Reyes Barcelo AA, Gonzalez-Velasquez FJ, MossMA(2009) Soluble aggregates of the amyloid-beta peptide are trapped by serum albumin to enhance amyloid-beta activation of endothelial cells. J Biol Eng 3, 5.
31. Algamal M, Milojevic J, Jafari N, Zhang W, Melacini G (2013) Mapping the Interactions between the Alzheimer's A-peptide and human serum albumin beyond domain resolution. Biophys J 105, 1700-1709.
32. Reese LC, Zhang WR, Dineley KT, Kayed R, Taglialatela G (2008) Selective induction of calcineurin activity and signaling by oligomeric amyloid beta. Aging Cell 7, 824-835.
33. Demuro A, Mina E, Kayed R, Milton SC, Parker I, Glabe CG (2005) Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J Biol Chem 280, 17294-17300.
34. Filali M, Lalonde R, Theriault P, Julien C, Calon F, Planel E (2012) Cognitive and non-cognitive behaviors in the triple transgenic mouse model of Alzheimer's disease expressing mutated APP, PS1, and Mapt (3xTg-AD) . Behav Brain Res 234, 334-342.
35. Stover KR, Campbell MA, Van Winssen CM, Brown RE (2015) Early detection of cognitive deficits in the 3xTg-AD mouse model of Alzheimer's disease. Behav Brain Res 289, 29-38.
36. Bohrmann B, Tjernberg L, Kuner P, Poli S, Levet-trafit B, Nordstedt C (1999) Endogenous proteins controlling amyloid-peptide polymerization. J Biol Chem 274, 15990-15995.
37. Stanyon HF, Viles JH (2012) Human serum albumin can regulate amyloid-peptide fiber growth in the brain interstitium: Implications for Alzheimer disease. J Biol Chem 287, 28163-28168.
38. Rabinovich-Nikitin I, Rakover IS, Becker M, Solomon B (2012) Beneficial effect of antibodies against-secretase cleavage site of APP on Alzheimer's-like pathology in tripletransgenic mice. PLoS One 7, e46650.
39. Oh K-J, Perez SE, Lagalwar S, Vana L, Binder L, Mufson EJ (2010) Staging of Alzheimer's pathology in triple transgenic mice: A light and electron microscopic analysis. Int J Alzheimers Dis 2010, pii: 780102.
40. Otvos L, Feiner L, Lang E, Szendrei GI, Goedert M, Lee VM (1994) Monoclonal antibody PHF-1 recognizes tau protein phosphorylated at serine residues 396 and 404. J Neurosci Res 39, 669-673.
41. Beach TG, Walker R, Mcgeer EG (1989) Patterns of gliosis in Alzheimer's disease and aging cerebrum. Glia 2, 420-436.
42. Vartak-Sharma N, Ghorpade A (2012) Astrocyte elevated gene-1 regulates astrocyte responses to neural injury: Implications for reactive astrogliosis and neurodegeneration. J Neuroinflammation 9, 195.
43. Caruso D, Barron AM, Brown MA, Abbiati F, Carrero P, Pike CJ, Garcia-Segura LM,MelcangiRC(2013) Age-related changes in neuroactive steroid levels in 3xTg-AD mice. Neurobiol Aging 34, 1080-1089.
44. Dickstein DL, Biron KE, Ujiie M, Pfeifer CG, Jeffries AR, Jefferies WA (2006) Abeta peptide immunization restores blood-brain barrier integrity in Alzheimer disease. FASEB J 20, 426-433.
45. Carrano A, Hoozemans JJM, van der Vies SM, van Horssen J, de Vries HE, Rozemuller AJM (2012) Neuroinflammation and blood-brain barrier changes in capillary amyloid angiopathy. Neurodegener Dis 10, 329-331.
46. Desai MK, Sudol KL, Janelsins MC, Mastrangelo MA, Frazer ME, Bowers WJ (2009) Triple-transgenic Alzheimer's disease mice exhibit region-specific abnormalities in brain myelination patterns prior to appearance of amyloid and tau pathology. Glia 57, 54-65.
47. Behrendt G, Baer K, Buffo A, Curtis MA, Faull RL, Rees MI, Götz M, Dimou L (2013) Dynamic changes in myelin aberrations and oligodendrocyte generation in chronic amyloidosis in mice and men. Glia 61, 273-286.
48. Desai MK, Mastrangelo MA, Ryan DA, Sudol KL, Narrow WC, Bowers WJ (2010) Early oligodendrocyte/ myelin pathology in Alzheimer's disease mice constitutes a novel therapeutic target. Am J Pathol 177, 1422-1435.
49. Small DH, Mok SS, Bornstein JC (2001) Alzheimer's disease and Abeta toxicity: From top to bottom. Nat Rev Neurosci 2, 595-598.
50. Kirkitadze MD, Bitan G, Teplow DB (2002) Paradigm shifts in Alzheimer's disease and other neurodegenerative disorders: The emerging role of oligomeric assemblies. J Neurosci Res 69, 567-577.
51. Williams TL, Serpell LC (2011) Membrane and surface interactions of Alzheimer's A peptide-insights into the mechanism of cytotoxicity. FEBS J 278, 3905-3917.
52. Ferreira ST, Vieira MNN, De Felice. FG Soluble protein oligomers as emerging toxins in Alzheimer's and other amyloid diseases. IUBMB Life 59, 332-345.
53. Makrides V, Shen TE, Bhatia R, Smith BL, Thimm J, Lal R, Feinstein SC (2003) Microtubule-dependent oligomerization of tau. Implications for physiological tau function and tauopathies. J Biol Chem 278, 33298-33304.
54. Gendron TF, Petrucelli L (2009) The role of tau in neurodegeneration. Mol Neurodegener 4, 13.
55. Chabrier MA, Blurton-Jones M, Agazaryan AA, Nerhus JL, Martinez-Coria H, LaFerla FM (2012) Soluble A promotes wild-type tau pathology in vivo. J Neurosci 32, 17345-17350.
56. Lue LF, Rydel R, Brigham EF, Yang LB, Hampel H, Murphy GM, Brachova L, Yan S, Du, Walker DG, Shen Y, Rogers J (2001) Inflammatory repertoire of Alzheimer's disease and nondemented elderly microglia in vitro. Glia 35, 72-79.
57. Erickson MA, Banks WA (2013) Blood-brain barrier dysfunction as a cause and consequence of Alzheimer's disease. J Cereb Blood Flow Metab 33, 1500-1513.
58. De La Torre JC (2004) Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics. Lancet Neurol 3, 184-190.
59. Brkic M, Balusu XS,Wonterghem E, Van, Gorle N, Benilova I, Kremer A,VanHove I, Moons L, Strooper B, De, Kanazir S, Libert C, Vandenbroucke XRE (2015) Amyloid ( oligomers disrupt blood-CSF barrier integrity by activating matrix metalloproteinases. J Neurosci 35, 12766-12778.
60. Takeda S, Sato N, Ikimura K, Nishino H, Rakugi H, Morishita R (2013) Increased blood-brain barrier vulnerability to systemic inflammation in an Alzheimer disease mouse model. Neurobiol. Aging 34, 2064-2070.
61. Horiuchi M, Maezawa I, Itoh A,Wakayama K, Jin L-W, Itoh T, Decarli C (2012) Amyloid 1-42 oligomer inhibits myelin sheet formation in vitro. Neurobiol. Aging 33, 499-509.
62. Kotarba AE, Aucoin D, Hoos MD, Smith SO, Van Nostrand WE (2013) Fine mapping of the amyloid-protein binding site on myelin basic protein. Biochemistry 52, 2565-2573.
63. Liao M-C, Hoos MD, Aucoin D, Ahmed M, Davis J, Smith SO, Van Nostrand WE (2010) N-terminal domain of myelin basic protein inhibits amyloid beta-protein fibril assembly. J. Biol. Chem 285, 35590-35598.
64. Clarner T, Diederichs F, Berger K, Denecke B, Gan L, van der Valk P, Beyer C, Amor S, Kipp M (2012) Myelin debris regulates inflammatory responses in an experimental demyelination animal model and multiple sclerosis lesions. Glia 60, 1468-1480.
65. Bogie JF, Jorissen W, Mailleux J, Nijland PG, Zelcer N, Vanmierlo T, Van Horssen J, Stinissen P, Hellings N, Hendriks JJ (2013) Myelin alters the inflammatory phenotype of macrophages by activating PPARs. Acta Neuropathol Commun 1, 43.
66. Baltanás FC,Weruaga E,Valero J, Recio JS, Alonso JR (2009) Albumin attenuates DNA damage in primary-cultured neurons. Neurosci Lett 450, 23-26.
67. Boada M, Ortiz P, Anaya F, Hernández I, Muñoz J, Núñez L, Olazarán J, Roca I, Cuberas G, Tárraga L, Buendia M, Pla RP, Ferrer I, Páez A (2009) Amyloid-targeted therapeutics in Alzheimer's disease: Use of human albumin in plasma exchange as a novel approach for Abeta mobilization. Drug News Perspect 22, 325-339.
68. Pascale CL, Miller MC, Chiu C, Boylan M, Caralopoulos IN, Gonzalez L, Johanson CE, Silverberg GD (2011) Amyloidbeta transporter expression at the blood-CSF barrier is agedependent. Fluids Barriers CNS 8, 21.
69. Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B, Holtzman DM, Miller CA, Strickland DK, Ghiso J, Zlokovic BV (2000) Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 106, 1489-1499.
70. Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, Yarasheski KE, Bateman RJ (2010) Decreased clearance of CNS-amyloid in Alzheimer's disease. Science 330, 2010.
71. Lemere CA (2013) Immunotherapy for Alzheimer's disease: Hoops and hurdles. Mol Neurodegener 8, 36.